IDSA: Intranasal Live-Attenuated COVID-19 Vaccine Induces Response
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Oct. 17, 2023 -- Two doses of a novel intranasal live-attenuated COVID-19 vaccine, CoviLiv, induce poly-antigenic immune response, according to a study presented at the annual meeting of the Infectious Diseases Society of America (IDWeek), held from Oct. 11 to 15 in Boston.
Johanna Kaufmann, Ph.D., from Codagenix in Cambridge, Massachusetts, and colleagues characterized humoral immune responses in sera from six participants (at days 1, 29, and 57) with a spike-specific immunoglobulin G (IgG) enzyme-linked immunosorbent assay and microneutralization (MNT) and pseudovirus neutralization (PVN) assays. In peripheral blood mononuclear cells, T-cell functionality was analyzed.
The researchers found that all participants exceeded a twofold increase in spike-specific IgG with a geometric mean fold rise of 19.5 on day 57 after two doses of CoviLiv. At this time point, neutralizing antibodies were induced 2.6- and 4.9-fold using MNT and PVN, respectively. On day 36 after vaccination, the interferon-γ response by ELISpot after restimulation with the SNMO peptide pool increased 4.5- and 2.5-fold in the two- and one-dose cohorts, respectively. After placebo vaccination or in any group after restimulation with spike-only peptides, there was no increase seen in interferon-γ response. Significant regimen-dependent SNMO-specific increases in interferon-γ, interleukin-2, and tumor necrosis factor-α response was confirmed by intracellular cytokine staining, especially in the CD4+ T-cell subset, including induction of polyfunctional CD4+ T cells.
"The study findings provide a glimpse into what could be the next generation of COVID-19 vaccines that provide differentiated protection to more people," Kaufmann said in a statement. "Vaccine administration by nose and easier storage can increase access to vaccinations for underserved areas across the world."
Codagenix engineered the CoviLiv vaccine.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Further Support and Information on COVID-19
Read this next
No Evidence That Live Vaccines Are Unsafe for Patients on Dupilumab
FRIDAY, June 14, 2024 -- There is no evidence to suggest that administration of live vaccines to patients receiving dupilumab is unsafe, and vaccine efficacy is not affected by...
Residual Risk Seen for Death, Postacute Sequelae in Third Year After COVID-19 Hospitalization
THURSDAY, June 13, 2024 -- For individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the risks for death and postacute sequelae of COVID-19...
Systemic Side Effects of COVID-19 Vaccine Tied to Greater nAB Response
TUESDAY, June 11, 2024 -- Short-term systemic side effects of the severe acute respiratory coronavirus 2 (SARS-CoV-2) mRNA vaccine are associated with greater long-lasting...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.